Dean Hakanson co-wrote this blog post with Ed Schoonveld. This blog post was originally published on The Price of Global Health.
Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?